$APVO
Aptevo Therapeutics Inc.

2018 Q1 Form 10-Q Financial Statement

#000156459018012733 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $4.071M $2.142M
YoY Change 90.06% -73.45%
Cost Of Revenue $1.781M $488.0K
YoY Change 264.96% -86.17%
Gross Profit $2.290M $1.654M
YoY Change 38.45% -63.56%
Gross Profit Margin 56.25% 77.22%
Selling, General & Admin $7.592M $10.55M
YoY Change -28.02% 11.98%
% of Gross Profit 331.53% 637.67%
Research & Development $8.199M $5.913M
YoY Change 38.66% -27.01%
% of Gross Profit 358.03% 357.5%
Depreciation & Amortization $587.0K $841.0K
YoY Change -30.2% 0.6%
% of Gross Profit 25.63% 50.85%
Operating Expenses $15.79M $16.46M
YoY Change -4.06% -6.05%
Operating Profit -$13.50M -$9.539M
YoY Change 41.53% -26.52%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$353.0K -$406.0K
YoY Change -13.05% -607.5%
Pretax Income -$13.85M -$9.945M
YoY Change 39.27% -22.91%
Income Tax -$820.0K
% Of Pretax Income
Net Earnings -$13.85M -$9.945M
YoY Change 39.31% -22.84%
Net Earnings / Revenue -340.31% -464.29%
Basic Earnings Per Share -$0.63 -$0.48
Diluted Earnings Per Share -$8.822M -$6.723M
COMMON SHARES
Basic Shares Outstanding 22.03M 20.76M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $61.70M $60.90M
YoY Change 1.31% 1864.52%
Cash & Equivalents $23.47M $14.41M
Short-Term Investments $49.80M $46.90M
Other Short-Term Assets $6.630M $6.500M
YoY Change 2.0% 20.37%
Inventory $1.285M $8.100M
Prepaid Expenses $4.093M
Receivables $3.098M $1.900M
Other Receivables $0.00 $0.00
Total Short-Term Assets $77.20M $77.40M
YoY Change -0.26% 118.64%
LONG-TERM ASSETS
Property, Plant & Equipment $5.900M $6.400M
YoY Change -7.81% 39.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.20M
YoY Change
Total Long-Term Assets $23.00M $20.40M
YoY Change 12.75% -77.95%
TOTAL ASSETS
Total Short-Term Assets $77.20M $77.40M
Total Long-Term Assets $23.00M $20.40M
Total Assets $100.2M $97.80M
YoY Change 2.45% -23.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.300M $8.800M
YoY Change -17.05% -27.87%
Accrued Expenses $2.100M $2.500M
YoY Change -16.0% 13.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.300M
YoY Change
Total Short-Term Liabilities $17.30M $14.50M
YoY Change 19.31% -22.46%
LONG-TERM LIABILITIES
Long-Term Debt $14.00M $18.40M
YoY Change -23.91%
Other Long-Term Liabilities $600.0K $3.400M
YoY Change -82.35% -2.86%
Total Long-Term Liabilities $14.60M $21.80M
YoY Change -33.03% 522.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.30M $14.50M
Total Long-Term Liabilities $14.60M $21.80M
Total Liabilities $31.80M $36.30M
YoY Change -12.4% -4.61%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.36M $61.50M
YoY Change
Total Liabilities & Shareholders Equity $100.2M $97.80M
YoY Change 2.45% -13.14%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$13.85M -$9.945M
YoY Change 39.31% -22.84%
Depreciation, Depletion And Amortization $587.0K $841.0K
YoY Change -30.2% 0.6%
Cash From Operating Activities -$16.98M -$12.03M
YoY Change 41.13% -14.74%
INVESTING ACTIVITIES
Capital Expenditures $473.0K $794.0K
YoY Change -40.43% -25.86%
Acquisitions
YoY Change
Other Investing Activities $23.99M -$2.040M
YoY Change -1275.98%
Cash From Investing Activities $23.51M -$2.830M
YoY Change -930.81% 164.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -556.0K 19.20M
YoY Change -102.9% 40.97%
NET CHANGE
Cash From Operating Activities -16.98M -12.03M
Cash From Investing Activities 23.51M -2.830M
Cash From Financing Activities -556.0K 19.20M
Net Change In Cash 5.978M 4.338M
YoY Change 37.81% -378.08%
FREE CASH FLOW
Cash From Operating Activities -$16.98M -$12.03M
Capital Expenditures $473.0K $794.0K
Free Cash Flow -$17.45M -$12.82M
YoY Change 36.08% -15.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
73688000
CY2018Q1 us-gaap Short Term Investments
ShortTermInvestments
49824000
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3098000
CY2018Q1 us-gaap Inventory Net
InventoryNet
1285000
CY2018Q1 us-gaap Other Assets Current
OtherAssetsCurrent
6630000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
400000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4022000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6710000
CY2018Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5873000
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4093000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4626000
CY2018Q1 apvo Sales Rebates And Discounts Payable
SalesRebatesAndDiscountsPayable
835000
CY2017Q4 apvo Sales Rebates And Discounts Payable
SalesRebatesAndDiscountsPayable
623000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
400000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
95084000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
11243000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6080000
CY2017Q4 us-gaap Assets
Assets
117007000
CY2017Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7350000
CY2018Q1 apvo Cost Credit Of Product Sales
CostCreditOfProductSales
1781000
CY2017Q1 apvo Cost Credit Of Product Sales
CostCreditOfProductSales
-1727000
CY2017Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
406000
CY2018Q1 us-gaap Sales Revenue Net
SalesRevenueNet
4071000
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
2142000
CY2018Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
407000
CY2018Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-13908000
CY2017Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-11714000
CY2018Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
54000
CY2017Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
2592000
CY2017Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
823000
CY2018Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
54000
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1769000
CY2018Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.63
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.56
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.08
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-13854000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-9945000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
957000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-123000
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
257000
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1342000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2830000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22025268
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20757111
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13832000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9953000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
717000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1678000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
587000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
841000
CY2018Q1 apvo Non Cash Interest Expense
NonCashInterestExpense
247000
CY2017Q1 apvo Non Cash Interest Expense
NonCashInterestExpense
149000
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
187000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-97000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
806000
CY2018Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-3371000
CY2017Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4916000
CY2017Q1 apvo Increase Decrease In Assets And Liabilities Held For Sale
IncreaseDecreaseInAssetsAndLiabilitiesHeldForSale
-2191000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16978000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12027000
CY2018Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
25929000
CY2017Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
8102000
CY2018Q1 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
54000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
473000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
794000
CY2018Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1998000
CY2017Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
10138000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
23512000
CY2017Q1 apvo Settlement Of Contribution Receivable From Former Parent
SettlementOfContributionReceivableFromFormerParent
20000000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
186000
CY2018Q1 apvo Payment Of Tax Liability For Vsted Equity Awards
PaymentOfTaxLiabilityForVstedEquityAwards
742000
CY2017Q1 apvo Payment Of Tax Liability For Vsted Equity Awards
PaymentOfTaxLiabilityForVstedEquityAwards
805000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-556000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19195000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5978000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4338000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17495000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10076000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23473000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14414000
CY2017Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
56000
CY2018Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
658000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
482000
CY2018Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
576000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
490000
CY2018Q1 us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
LIBOR
CY2018Q1 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0760
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
717000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1678000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p></div>
CY2018Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Reclassifications</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:6pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our financial statements reflect all adjustments that we consider to be necessary for the fair presentation of our results, due to changes in accounting policies, sale of our Hyperimmune Business, and the reclassification of restricted cash.</p></div>
CY2016Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
35000000
CY2016Q3 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
20000000
CY2017Q3 apvo Revenue Recognition Of Net Commercial Product Date To Be Achieved
RevenueRecognitionOfNetCommercialProductDateToBeAchieved
2018-06-30
CY2018Q1 us-gaap Revenue Recognition Milestone Method Description
RevenueRecognitionMilestoneMethodDescription
The date on which the term loans begin to amortize will be extended to February 1, 2019 if we achieve net commercial product revenues of $16.0 million for the twelve month period ending June 30, 2018 and maintains such level of net commercial product revenues for each quarter prior to February 1, 2019 thereafter.
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
997000
CY2018Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
400000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
400000
CY2018Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11243000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10000000
CY2018Q1 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
51000
CY2018Q1 apvo Number Of Revenue Generating Product
NumberOfRevenueGeneratingProduct
1
CY2018Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
64284000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
84685000
CY2018Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q1 us-gaap Cash
Cash
7588000
CY2017Q4 us-gaap Cash
Cash
6098000
CY2018Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
4242000
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018Q1 apvo Percentage Limitation Of Taxable Income For Net Operating Losses Carryforward
PercentageLimitationOfTaxableIncomeForNetOperatingLossesCarryforward
0.800
CY2018Q1 apvo Tax Cuts And Jobs Act Description
TaxCutsAndJobsActDescription
On December 22, 2017, the President of the United States signed into law Public Law No. 115-97, commonly referred to as the Tax Reform Act, following its passage by the United States Congress. The Tax Act made significant changes to U.S. federal income tax laws, including reduction of the corporate tax rate from 35.0% to 21.0%, limitation of the deduction for net operating losses to 80.0% of current year taxable income and elimination of net operating loss carrybacks, one-time taxation of offshore earning at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions.

Files In Submission

Name View Source Status
0001564590-18-012733-index-headers.html Edgar Link pending
0001564590-18-012733-index.html Edgar Link pending
0001564590-18-012733.txt Edgar Link pending
0001564590-18-012733-xbrl.zip Edgar Link pending
apvo-10q_20180331.htm Edgar Link pending
apvo-20180331.xml Edgar Link completed
apvo-20180331.xsd Edgar Link pending
apvo-20180331_cal.xml Edgar Link unprocessable
apvo-20180331_def.xml Edgar Link unprocessable
apvo-20180331_lab.xml Edgar Link unprocessable
apvo-20180331_pre.xml Edgar Link unprocessable
apvo-ex311_7.htm Edgar Link pending
apvo-ex312_9.htm Edgar Link pending
apvo-ex321_8.htm Edgar Link pending
apvo-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending